RxSight, based in Aliso Viejo, California, specializes in ophthalmic products and continues to be an active player in the medical technology sector. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities.
RxSight, based in Aliso Viejo, California, specializes in ophthalmic products and continues to be an active player in the medical technology sector. The company maintains a solid balance sheet with more cash than debt, positioning it well for future growth opportunities.
RxSight, based in Aliso Viejo, California, specializes in ophthalmic products and continues to be an active player in the medical technology sector.
In other recent news, RxSight Inc. has been the subject of several recent analyst adjustments. Stifel cut its rating on the company’s stock and cut its price target due to concerns about competition and international expansion efforts. The company’s decision follows a review of RxSight’s preliminary results for the fourth quarter of 2024, which reported total revenue of $40.2 million, in line with Stifel and consensus estimates.
In contrast, Needham & Company maintained a positive view on RxSight, reiterating a Buy rating. The company’s 2025 revenue forecast exceeded consensus estimates, projecting revenues between $185 million and $197 million. However, Stifel and Wells Fargo (NYSE: ) downgraded RxSight shares due to slowing adoption projections and limited growth potential.
UBS initiated coverage on RxSight with a Buy rating, noting the company’s strong position in the US cataract surgery market and forecasting sales growth of over 20% through 2028. These recent developments reflect analysts’ differing perspectives on RxSight’s future.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
